<DOC>
	<DOCNO>NCT01480167</DOCNO>
	<brief_summary>The objective post market clinical investigation evaluate clinical effectiveness minimally invasive vertebral augmentation procedure , Radiofrequency-Targeted Vertebral Augmentation ( RF-TVA ) compare non-operative management ( NOM ) treatment appropriately diagnose acute ( ≤ 8 week ) painful osteoporotic vertebral compression fracture ( VCF ) .</brief_summary>
	<brief_title>The PRIORi-T Trial -- Prospective Randomized Investigation Radiofrequency Targeted Vertebral Augmentation</brief_title>
	<detailed_description>This multi-center , prospective , randomize , post marketing clinical trial design evaluate clinical effectiveness minimally invasive procedure , Radiofrequency-Targeted Vertebral Augmentation ( RF-TVA ) , compare Non Operative Management ( NOM ) treatment appropriately diagnose , acute ( ≤ 8 week ) , painful , osteoporotic vertebral compression fracture . Eligible subject randomly allocate receive either RF-TVA NOM 1:1 randomization ratio . Subjects follow 12 month post procedure . Primary effectiveness determine compare Visual Analogue Scale treatment group back pain baseline 1-month post procedure visit treatment group 1-month . Up 15 site participate trial .</detailed_description>
	<mesh_term>Fractures , Compression</mesh_term>
	<criteria>1 . Subject ≥ 21 ≤ 90 year age . 2 . Subject one ( 1 ) three ( 3 ) painful vertebral compression fracture ( ) T5L5 due primary secondary osteoporosis ( i.e . nonmalignant ) recent history sudden onset pain area index vertebra ( e ) . 3 . Subject 's index vertebra ( e ) confirm active source back pain evidence concordant pain bone marrow edema via magnetic resonance imaging ( MRI ) Computerized Tomography ( CT ) plus bone scan . 4 . Subject history vertebral fracturerelated back pain ≤ 8 week old time enrollment ( confirmed medical history ) . 5 . Subject pain related VAS score ≥ 5 scale 0 10 time enrollment . Pain represent bad level back pain standing , walk elevate chair , bed , car precede 24 hour associate index vertebra ( e ) . 6 . Subject Roland Morris Disability Questionnaire ( RDQ ) score ≥ 10 scale 0 24 time enrollment . 7 . Subject suitable candidate minimally invasive VCF procedure . 8 . Subject sufficient mental physical capacity comply Investigational Plan requirement willing able provide inform consent ; agree release medical information purpose study ; agree comply Investigational Plan requirement return specify followup evaluation . 9 . Subject male ; document infertile female ( either postmenopausal surgical contraception ) ; nonpregnant , nonlactating female childbearing potential agrees use medically accept method birth control throughout duration trial . 1 . Subject 's VCF morphology deem unsuitable RFTVA judgment Investigator . 2 . Subject require additional nonkyphoplasty vertebroplasty surgical treatment index fracture . 3 . Subject surgery spine plan least one ( 1 ) month follow enrollment . 4 . Subject highenergy traumarelated and/or , nonosteoporotic vertebral fracture . 5 . Subject spinal cord compression significant canal compromise require decompression , judgment investigator . 6 . Subject neurologic deficit associate vertebral level ( ) treat severe radiculopathy ( e.g . myelopathy , cauda equina syndrome ) . 7 . Subject irreversible coagulopathy bleed disorder . 8 . Subject require , time enrollment , use highdose steroid ( e.g . ≥ 100 mg prednisone 20 mg dexamethasone per day ) , intravenous ( IV ) pain medication , nerve block control chronic back pain unrelated index VCF ( ) . 9 . Subject significant clinical comorbidities may potentially interfere collection data concern pain function . 10 . Subject know allergy device material ( e.g . polymethylmethacrylate ( PMMA ) barium ) . 11 . Subject contraindication local general anesthesia . 12 . Subject medical and/or surgical condition contrary kyphoplasty vertebroplasty procedure ( e.g . presence local systemic infection ) . 13 . Subject receive Worker 's Compensation . 14 . Subject prisoner .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>VCF</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Minimally Invasive</keyword>
	<keyword>Non-operative management</keyword>
	<keyword>Medical Management</keyword>
</DOC>